

# Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

Information for the public

Published: 29 August 2024

[www.nice.org.uk](http://www.nice.org.uk)

Pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy is available on the NHS. It is a possible treatment in adults for HER2-negative gastric (stomach) or gastro-oesophageal junction adenocarcinoma that:

- has not been treated before, and
- is locally advanced, cannot be removed surgically or has spread to other parts of the body, and
- expresses a protein called PD-L1 with a combined positive score of 1 or more.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpages on oesophageal cancer](#) or [stomach cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Heartburn Cancer UK \(HCUK\)](#), 01256 338668
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6452-9